Glenmark Generics Inc has launched an anti-inflammatory cream in the US market. The company is a US subsidiary of Glenmark Generics, part of Mumbai-based Glenmark Pharmaceuticals. The cream is claimed to provide relief for dermatoses in adults and moderate dermatitis (skin inflammations) in patients under 18.
Derived from Locoid Lipocream, the hydrocortisone butyrate cream, approved for sale in September, will enter a $37-million market in the US. It will enjoy 180 days of exclusivity because it was the first generic company to file for an Abbreviated New Drug Application for the product, Glenmark said in a filing with the BSE.
Glenmark currently boasts 90 authorised products in the US and has 56 drug applications pending approval by the US Food and Drug Administration. The company is looking at technological partnerships to widen its US portfolio, said the release.